Accipiter denies the accusation and most of the claims were recently dismissed.

FORBES: OutFront

Still pending: Papastavrou's suit against Accipiter Life Sciences Fund II, asserting it mismanaged a rash of redemptions and left little for investors like Aris.

FORBES: Companies, People, Ideas